Premier Research and Centogene Enter Partnership to De-Risk Rare Disease Clinical Development

The contract research organization Premier Research and the biodata company Centogene have entered into a strategic partnership to provide end-to-end support in rare disease clinical trials.

Photo: Kim Stratton, CEO of Centogene

The collaboration aims to improve patient identification, stratification, recruitment, and enrollment, with the goal of increasing the likelihood of study success.

“Precision, advanced analysis, and access is where our Biodatabank makes a qualitative difference,” Kim Stratton, CEO of Centogene, said. “In partnering with Premier Research, our first strategic CRO partner, we are extending our strategy and expanding our commercialization opportunities to provide pharma partners with yet another model to work with us.”

The small patient populations coupled with the complexities of disease diagnosis create significant challenges in enrolling rare disease clinical trial participants. The companies said by combining Premier Research’s deep expertise in rare disease product development with advanced insights generated from the Centogene Biodatabank and multiomic reference laboratories will support the faster identification of eligible patients.

Author: Rare Daily Staff